Vaginal Lactobacillus bacterial strains largely perform better than strains currently used in probiotics for vaginal health, according to a study published June 4 in the open-access journal PLOS Pathogens by Jo-Ann Passmore of the University of Cape Town, and colleagues. The findings suggest that a vaginal health probiotic that includes top-performing vaginal Lactobacillus strains may improve treatment options for bacterial vaginosis.
Lactobacillus species in the lower reproductive tract of healthy women lower vaginal pH and protect against sexually transmitted infections. But women commonly suffer from bacterial vaginosis—a disruption in the optimal Lactobacillus-dominated genital microbiota—resulting in higher vaginal pH as well as vaginal discharge and inflammation. Bacterial vaginosis is associated with adverse pregnancy outcomes and a higher risk of sexually transmitted infections, including HIV. Although antibiotics are the standard of care for bacterial vaginosis, most cases recur within six months. Probiotics that include Lactobacilli have been explored to improve the durability of treatment, but the majority of products do not contain species commonly found in the vagina. There is an urgent need for the development of additional well-designed probiotics for vaginal health.
In the new study, Passmore and colleagues compared 57 vaginal Lactobacillus strains from young African women to strains from commercial probiotic products for vaginal health. They analyzed their growth at varying pH values, ability to lower pH and produce antimicrobial products, pathogen inhibition, and susceptibility to antibiotics. Several vaginal strains exhibited better probiotic profiles than commercial strains, suggesting that they would be beneficial in the development of probiotic treatments for bacterial vaginosis. Moreover, whole-genome sequencing of the five best-performing vaginal strains revealed that they would likely be safe and not pose a risk of antimicrobial resistance. According to the authors, a wider range of well-characterized Lactobacillus-containing probiotics may improve treatment outcomes for bacterial vaginosis, and lower the risk of adverse pregnancy outcomes and sexually transmitted infections.
“Few probiotics aimed at promoting vaginal health contain Lactobacillus spp. that commonly colonize the lower genital tracts of African women,” the authors add. “The discovery and use of novel vaginal probiotic strains in such women may improve the durability of bacterial vaginosis treatments and towards this end Happel et al. (2020) evaluated a multitude of vaginal Lactobacillus strains and identified some that should be tested as vaginal probiotics in clinical trials in Africa.”
Researchers show how probiotics benefit vaginal health
Happel A-U, Kullin B, Gamieldien H, Wentzel N, Zauchenberger CZ, Jaspan HB, et al. (2020) Exploring potential of vaginal Lactobacillus isolates from South African women for enhancing treatment for bacterial vaginosis. PLoS Pathog 16(6): e1008559. doi.org/10.1371/journal.ppat.1008559
Probiotics with top-performing Lactobacillus strains may improve vaginal health (2020, June 4)
retrieved 4 June 2020
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.
- COVID case rates hit new high for England, study finds - April 7, 2022
- Govt’s focus on affordable healthcare ensured significant savings for poor, middle class: PM Modi - April 7, 2022
- SRL Diagnostics and Skye Air Mobility collaborate to transport pathology samples using drone logistics - April 6, 2022
- Healthineers sets up new production line of CT scanners in Bengaluru under PLI scheme - April 6, 2022
- Lupin inks licensing pact with Alvion to market drugs in Southeast Asia - April 6, 2022
- Yoga Mahotsav: Ayush Ministry to organise event to demonstrate common yoga on World Health Day - April 6, 2022
- LordsMed forays into the medtech space with launch of health ATMs ‘Lords Sehat’ - April 5, 2022
- ‘Friendly viruses’ can be the next big thing in the history of medical research and more - April 5, 2022
- No setback to Bharat Biotech even as WHO suspends Covaxin UN supply: Sources - April 4, 2022
- Govt panel recommends Serum’s Covovax dose for kids aged 12 and above - April 4, 2022